Literature DB >> 1714278

Mechanism of anti-inflammatory action of etodolac.

K Inoue1, A Motonaga, T Nishimura, M Yokota, N Miki, H Fujisawa, F Ueda, Y Shibata, K Kimura.   

Abstract

The effect of etodolac (CAS 41340-25-4) on the inflammatory reactions induced by histamine and bradykinin was compared with that of indomethacin and other nonsteroidal anti-inflammatory drugs. Etodolac (50 mg/kg p.o.), indomethacin (20 mg/kg p.o.), diclofenac Na (20 mg/kg p.o.) and acetylsalicylic acid (200 mg/kg p.o.) had no effect on the increase of vascular permeability induced by histamine or bradykinin and on passive cutaneous anaphylaxis in rats. Etodolac (5, 10 and 20 mg/kg p.o.) suppressed concanavalin A-induced paw edema in rats. Etodolac (10 mg/kg p.o.) and bromelain (10 mg/kg i.v.) significantly suppressed the heat-induced elevation of bradykinin in perfusates of rat paws, but indomethacin (20 mg/kg p.o.) and diclofenac Na (20 mg/kg p.o.) did not. Etodolac inhibited bradykinin-forming enzyme activity in a concentration-dependent manner (IC50 = 1.5 x 10[-4) mol/l). These results suggest that etodolac is a unique nonsteroidal anti-inflammatory drug which can inhibit bradykinin formation, unlike indomethacin or diclofenac Na.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714278

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

Review 1.  Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.

Authors:  J A Balfour; M M Buckley
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Effects of fepradinol on rat acute models of vascular permeability and leucocyte migration.

Authors:  J M Masso; A M Villar; J R Conde; J Martorell
Journal:  Agents Actions       Date:  1994-10

3.  Effect of etodolac on type-II collagen-induced arthritis in mice.

Authors:  K Inoue; A Motonaga; H Suzuka; H Yoshifusa; H Fujisawa; T Nishimura; Y Inoue; F Ueda; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1993-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.